Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban added to lenvatinib plus sintilimab for advanced hepatocellular carcinoma
ChiCTR2000040540Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban, lenvatinib and sintilimab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
rivaroxabanlenvatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040540.